Chemotherapy
Twenty five patients did not receive chemotherapy: 19/25 (76%) had
stage I disease of whom 16 are alive and three are lost to follow-up,
presumed alive. Three had stage II disease of whom two died of disease
and one is a survivor. Two had stage III disease and one stage IV
disease; all of whom died.
Chemotherapy was administered to 192 patients: 88 (45.8%) patients
received JEb, 85 (44.2%) BEP, seven (3.6%) PEb and 12 (6.3%) a
variety of non-standard regimens.
There were 100 medical treatment-related events occurred in 61 patients
(Table 5), the commonest acute effects being cytopaenias (24) and
febrile neutropaenia (11) with hearing loss (19) the commonest
subacute/late effect.